[ad_1]
An experimental vaccine, developed by scientists more than 40 years ago, showed an immune response to humans and was successful in protecting monkeys from infection, according to a study published in the Lancet medical journal. The vaccine will be tested in the next phase of the experimental procedure, after the drug has been proven safe in humans and will be tested on 2,600 women in South Africa to determine if it will succeed in preventing AIDS.
Aliens warn that despite the encouraging results so far, it does not guarantee success for a drug in the next experimental phase called "HTNV705" or "Imbukudu", meaning rock in Zulu.
Dan Barroch, a study supervisor and professor at Harvard University, told AFP: "Although" the vaccine's success in protecting two-thirds of the monkeys in a laboratory experience does not mean that it will protect humans, so we must wait for the results of the study before knowing if,
Imbukudu research results should be published in 2021 or 2022.
Baroch said: "This is the fifth vaccine that will test its efficacy on humans in the 35-year history of AIDS worldwide."
A single vaccine, called RV144 , showed a form of prevention of the disease. RIV 144 was announced in 2009 to reduce the risk of HIV infection by 31.2% among 16,000 Thai volunteers, but it was not enough to clbadify it as antiretroviral.
Volunteers were randomly badigned to a group of vaccines or a placebo and four were administered for 48 weeks.
The study used vaccine formulations called "mosaic vaccines".
These combinations brought different types of HIV to provoke a response, at the moment the body attacks bacteriostatic, against viral strains in different parts of the world.
Baroch says the vaccine "has the most powerful immune response (at high levels) on humans. "
Tests showed the vaccine was safe, but five participants recalled Negative effects, such as stomach upset, diarrhea, dizziness or back pain.
In a separate study, the drug proved the complete prevention of AIDS in two-thirds of the 72 monkeys. Experiments with six doses of pseudo-HIV virus
Franko Venter, M.
"We were at this stage before, when we developed promising candidate vaccines but they did not develop."
He continued, "This property is new." In many ways, it's an exciting vaccine, but we still have a long way to go. "
Jean Daniel Lilliver of the Vaccine Research Institute in France stated that the vaccine was probably not "final" but perhaps "extraordinary progress" "
According to figures from the World Health Organization, it is estimated that 37 million people are living with AIDS.
Nearly 1.8 million people are infected with the disease and nearly one million people die each year.
Estimates of 80 million people have been diagnosed with HIV since the diagnosis of the disease for the first time in the early 1980s.
About 35% of the disease has died in the world up to now . A drug is ultimately effective because the HIV virus develops easily and can hide in cells and escape the immune system to reappear and spread after years.
AIDS patients currently rely on therapies to inhibit the virus. The male is the first way to prevent transmission through communication But most prefer to use the inactivation treatment of the virus as preventive measures.
The results of the latest study come at a time when the International AIDS Conference will be held in Amsterdam from 23 July to 27 July.
[ad_2]
Source link
